NASDAQ : VCRE
Vicore Pharma Holding AB (publ) — Key statistics
Healthcare · Biotechnology · Sweden
Last price 9.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 277.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 276.27M |
| Enterprise Value | 184.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 281.53M |
| Shares Change (YoY) | +32.83% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.89% |
| Owned by Institutions (%) | 33.52% |
| Float | 200.80M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 674.53 |
| Forward PS | 1,737.16 |
| PB Ratio | 3.16 |
| P/TBV Ratio | 3.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 450.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.68 |
| Quick Ratio | 12.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -56.99% |
| Return on Assets (ROA) | -34.35% |
| Return on Invested Capital (ROIC) | -37.17% |
| Return on Capital Employed (ROCE) | -61.14% |
| Weighted Average Cost of Capital (WACC) | 4.75% |
| Revenue Per Employee | $8,959 |
| Profits Per Employee | -$1.13M |
| Employee Count | 46 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 26,723 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.09 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.09 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 51.81 |
| Average Volume (20 Days) | 24,984 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1,028 |
| Short Previous Month | 9,857 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 412,092 |
| Gross Profit | 412,092 |
| Operating Income | -54.05M |
| Pretax Income | -51.77M |
| Net Income | -51.80M |
| EBITDA | n/a |
| EBIT | -54.05M |
| Loss Per Share | -$1.95 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 93.44M |
| Total Debt | n/a |
| Net Cash | 93.44M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 88.08M |
| Book Value Per Share | 0.31 |
| Working Capital | 88.02M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -46.76M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -46.76M |
| FCF Per Share | -$0.17 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -13,116.96% |
| Pretax Margin | -12,563.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.83% |
| Shareholder Yield | -32.83% |
| Earnings Yield | -20.04% |
| FCF Yield | -16.82% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $29.97 |
| Price Target Difference | 207.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -8.41% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |